Login / Signup

Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan.

Stefan KohlerNorman SitaliJay AcharNicolas Paul
Published in: ERJ open research (2022)
Introducing new and shorter TB drug regimens could increase the cost of TB programmes with low drug resistance rates and decrease the cost of TB programmes with high drug resistance rates.
Keyphrases
  • mycobacterium tuberculosis
  • adverse drug
  • drug induced
  • randomized controlled trial
  • pulmonary tuberculosis
  • hiv aids
  • hepatitis c virus
  • human immunodeficiency virus
  • hiv infected